Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

76.58
Delayed Data
As of Jun 28
 +4.14 / +5.72%
Today’s Change
55.00
Today|||52-Week Range
133.62
-29.39%
Year-to-Date
Why Agenus' Stock Has Stumbled in 2016
Jun 27 / MotleyFool.com - Paid Partner Content
Incyte Gets FDA Approval For Breakthrough Therapy Status For Its Ruxolitinib
Jun 23 / Benzinga - Paid Partner Content
Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
Jun 24 / Zacks.com - Paid Partner Content
Better Buy: Johnson & Johnson vs. Eli Lilly
Jun 15 / MotleyFool.com - Paid Partner Content
Incyte Reports Epacadostat Combination Study Initiation
Jun 23 / Zacks.com - Paid Partner Content